Introduction
Mycobacterium tuberculosis (MTB) is a pathogenic bacterial species in the genus Mycobacterium and is the causative agent of most cases of tuberculosis. Tuberculosis is a common and often deadly infectious disease in humans [1, 2] . Tuberculosis is the most common opportunistic disease in persons infected with human immunodeficiency virus [3] . The genome of MTB is rich in lipid-metabolizing and P450 enzymes. The cell envelope of MTB is unique and is associated with its pathogenicity [4] . Mycolic acids are the major constituents of the protective barrier of cell envelope of MTB and are essential for survival, virulence, and antibiotic resistance [5] . Inhibitors of mycolic acid biosynthesis, such as isoniazid (INH), ethambutol (EMB), and pyrazinamide (PZA), are still in the frontline of antitubercular drugs [6] .
The discovery of the norfloxacin plays an important role in structure-activity relationships analysis of the fluoroquinolonic nucleus A-D, (Scheme 1) which led to the development of new derivatives with better solubility, higher antimicrobial activity, prolonged serum half-life, fewer adverse side effects, and both oral and parenteral routes of administration [7] [8] [9] . Naturally occurring bacterial DNA gyrase inhibitor such as novobiocin, a coumarin derivative E (Scheme 1), is known as antibacterial agents [10] . The coumarin drug inhibits ATPase activity of DNA gyrase by competing with ATP for binding to the subunit B of the enzyme. Owing to side effects, no pharmaceutically useful drug has been derived from the coumarins [11] . Although huge efforts have been dedicated to find a potent antibacterial agents that can overcome bacterial resistance, promising lead structures of DNA gyrase and topoisomerase IV enzyme inhibitors with novel mechanisms of action have not been found [12] . This reflects the inherent difficulties associated with the discovery and clinical testing of new candidates and the lack of significant pharmaceutical industry research in this area. Hence, the discovery and development of new drugs that effectively combat TB are accorded a great importance. In recent years, interest in pyrazoles has increased significantly because of their proven usefulness as intermediates in the preparation of new pharmaceuticals and agrochemicals [13] [14] [15] . Also, pyrazole derivatives F and G (Scheme 1) were identified as a new class of DNA gyrase and topoisomerase IV enzyme inhibitors [16] . Besides these, amides are well known for their therapeutic values since the amide group is an important pharmacophore. Antibiotics such as penicillins and cephalosporins have an amide group. The resistance toward available drugs is rapidly becoming a major worldwide problem. The necessity to design new compounds to overcome this resistance has become one of the most important areas of research today. Owing to our interest in synthesizing fascinating biologically active structurally diverse heterocycles [17] [18] [19] [20] , we recently reported the clean production of 1,1'-(5,5'-(1,4-phenylene)bis(3-aryl-1H-pyrazole-5,1-(4H,5H)-diyl)) diethanones, a novel series of bis pyrazole derivatives using sodium acetate/acetic anhydride triggered by ultrasound irradiation [21] , which accelerated the chemical reaction and mass transferred via the process of acoustic cavitation [22] . Extending the research in this area, we decided to investigate the antibacterial, antifungal, and antitubercular activities of the target compounds with the hope to develop some promising antimicrobial and antimycobacterial agents.
Experimental

Chemistry
Performing TLC assessed the reactions and the purity of the products. All the reported melting points are taken in open capillaries and were uncorrected. Sonication is performed on a Life Care-Fast Ultrasonic system (Life Care Equipments Pvt. Ltd., Mumbai, India) operating at a frequency of 45 kHz. The reaction flask is located in the maximum energy area in the bath and the addition or removal of water controlled the temperature of the water bath. IR spectra are recorded in KBr (pellet forms) on a Thermo 
In vitro antibacterial and antifungal activity by disc diffusion method
The in vitro activities of the compounds were tested in Sabourauds dextrose broth (SDB) (Hi-media, Mumbai) for fungi and nutrient broth (NB) (Hi-media, Mumbai) for bacteria by the disc diffusion method following the reported method [24] . The respective hydrochlorides of the test compounds 7-12 were dissolved in water to obtain 1 mg/mL stock solution and the different concentrations (100, 200, 500 ppm) were prepared from the stock solution. Seeded broth (broth-containing microbial spores) was prepared in NB from 24-h-old bacterial cultures on nutrient agar (Hi-media, Mumbai) at 37 ± 1°C while fungal spores from 1 to 7-day-old Sabourauds agar (Himedia, Mumbai) slant cultures were suspended in SDB. Sterile paper disc of 5-mm diameter was saturated with the three different concentrations and such discs were placed in each seeded agar plates. The petri plates were incubated in BOD incubator (Sigma Instruments, Chennai, India) at 37°C for bacteria and at 28°C for fungi. The zone of inhibition was recorded by visual observations after 24 h of inhibition for bacteria and after 72-96 h of inhibition for fungi. Moreover, the zone of inhibition was measured by excluding the diameter of the paper disc. Ciprofloxacin was used as standard for bacteria and fluconazole as standard for fungi under analogous conditions.
2.4.
In vitro antibacterial and antifungal activity by twofold serial dilution method MIC in μg/mL values was carried out by twofold serial dilution method [25] . The respective test compounds 7-12 were dissolved in dimethyl sulphoxide (DMSO) to obtain 1 mg/mL stock solution. Seeded broth (broth-containing microbial spores) was prepared in NB from 24-h-old bacterial cultures on nutrient agar (Hi-media, Mumbai) at 37 ± 1°C while fungal spores from 1 to 7-day-old Sabourauds agar (Hi-media, Mumbai) slant cultures were suspended in SDB. The colony forming units (cfu) of the seeded broth were determined by plating technique and adjusted in the range of 10 4 -10 5 cfu/mL. The final inoculums size was 10 5 cfu/mL for antibacterial assay and 1.1-1.5 × 10 2 cfu/mL for antifungal assay. Testing was performed at pH 7.4 ± 0.2 for bacteria (NB) and at a pH 5.6 for fungi (SDB). Exactly 0.4 mL of the solution of test compound was added to 1.6 mL of seeded broth to form the first dilution. One milliliter of this was diluted with a further 1 mL of seeded broth to give the second dilution and so on till six such dilutions were obtained. A set of assay tubes containing only seeded broth was kept as control. The tubes were incubated in BOD incubators at 37 ± 1°C for bacteria and 28 ± 1°C for fungi. MICs were recorded by visual observations after 24 h (for bacteria) and 72-96 h (for fungi) of incubation. Ciprofloxacin was used as standard for bacteria studies and fluconazole was used as standard for fungal studies.
In vitro antitubercular activity by luciferase reporter phage assay method
The preliminary antitubercular activity screening was conducted against M. tuberculosis H 37 Rv, INH-resistant M. tuberculosis by luciferase reporter phage assay method [26] at two different concentrations (1.00 and 2.00 mg/mL). Fifty microliter bacterial suspension equivalent to MacFarlands No. 2 standard was added to 400 mL of G7H9 with and without the test compound. For each sample, two drug-free controls and two drug concentrations were prepared and this setup was incubated for 72 h at 37°C. After incubation, 50 mL of the high titer Luciferase reporter phage (PhAE129) and 40 mL of 0.1 M CaCl 2 were added to all the vials and this setup was incubated at 37°C for 4 h. After incubation, 100 mL of the mixture was taken from each tube into a luminometer cuvette and equal amount of working D-Luciferin (0.3 mM in 0.05 M sodium citrate buffer, pH 4.5) solution was added. The RLU was measured after 10 s of integration in the Luminometer (Monolight 2010, Pegasus Scientific Inc., Rockvillae, USA). Duplicate readings were recorded for each sample and the mean was calculated. The percentage reduction in the RLU was calculated for each test sample and compared with control. The experiment was repeated when the mean RLU of the control was less than 1,000.
Results and discussion
Chemistry
Synthesis of 1,1'-(5,5'-(1,4-phenylene)bis(3-aryl-1H-pyrazole-5,1-(4H,5H)-diyl))diethanones 7-12 is carried out in excellent yields (Scheme 2 and Table 1 ) by the reaction of bis chalcones 1-6 with hydrazine hydrate catalyzed by anhydrous sodium acetate/acetic anhydride under ultrasonic irradiation method at 45°C within 10-20 min. It has been observed in the traditional classical method, the reaction mixture of bis chalcones 1-6 with hydrazine hydrate catalyzed by anhydrous sodium acetate in refluxing acetic anhydride for 5-8 h yield compounds 7-12 in moderate yields. However, when this reaction is performed under sonication method [27] , the reaction takes place rapidly within 10-20 min with excellent yields (Table 1) . In this study, acetic anhydride is the best solvent for the facile synthesis of bis pyrazoles, 7-12 in excellent yields without any solubility problem. In addition, in situ acetylation occurs in the course of the reaction because of solvent, acetic anhydride under the reaction conditions. The structures of the synthesized 1,1'-(5,5'-(1,4-phenylene)bis(3-aryl-1H-pyrazole-5,1-(4H,5H)-diyl))diethanones 7-12 are confirmed by FT-IR, MS, 1 H NMR, and 13 C NMR spectral studies and elemental analysis [21] . An array of biolabile 1,1'-(5,5'-(1,4-phenylene)bis(3-aryl-1H-pyrazole-5,1-(4H,5H)-diyl))diethanones 7-12 is tested for its antimicrobial activity by disc diffusion method against tested bacterial and fungal strains and the results are presented in Table 2 . The use of 1,1'-(5,5'-(1,4-phenylene)bis(3-phenyl-1H-pyrazole-5,1-(4H,5H)-diyl))diethanone 7 shows good zone of inhibitions against M. luteus. Excellent zone of inhibitions is noted against S. aureus, b-H. streptococcus, M. luteus, B. subtilis, V. cholerae, E. coli, K. pneumonia, A. niger, and M. gypseum by compound 8 which has electron withdrawing fluoro substituent at the para position of the phenyl ring. The usage of compound 9 which have electron withdrawing chloro substituent at the para position of the phenyl ring exhibits good zone of inhibitions against all the tested microorganisms except S. typhii, E. coli, and M. gypseum. Compound 10, which have electron withdrawing bromo substituent at the para position of the phenyl ring exhibits fine zone of inhibitions against all the tested bacterial strains except K. pneumonia. Excellent zone of inhibition is noticed by compound 10 against M. gypseum. The use of compound 11 which have electron-donating methyl substituent at the para position of the phenyl ring exhibits superior zone of inhibitions against S. flexneri, K. pneumonia, R. arrhizus, and M. gypseum. Also, the use of compound 12 which have electron donating methoxy substituent at the para position of the phenyl ring exerts higher zone of inhibitions against K. pneumonia, A. niger, and M. gypseum.
Antimicrobial activity of 1,1'-(5,5'-(1,4-phenylene)bis (3-aryl-1H-pyrazole-5,1-(4H, 5H)-diyl))diethanones by twofold serial dilution method 7-12
In vitro antimicrobial results by the twofold serial dilution method (Table 3) 
show that compound 7 exhibits good activities against M. luteus at a MIC value of 6.25 μg/mL. Admirable activities against b-H. streptococcus, M. luteus, K. pneumonia, and M. gypseum are displayed by compound 8 at a MIC value of 6.25 μg/mL, whereas it displays modest activities against S. aureus and B. subtilis at a MIC value of 12.5 μg/mL. The use of compound 9 displays higher activities against S. aureus, S. flexneri, V. cholerae, P. aeruginosa, A. flavus, and M. indicus at a MIC value of 6.25 μg/mL. Excellent antimicrobial activities are exhibited by compound 10 against S. typhii, S. flexneri, and M. gypseum at a MIC value of 6.25 μg/mL, whereas it exhibits superior activities against V. cholerae, E. coli, and P. aeruginosa at a MIC value of 12.5 μg/mL. The use of compound 11, which has electron donating methyl group at the para position of the phenyl ring, exhibits greater activities against K. pneumonia and M. gypseum at a MIC value of 6.25 μg/mL. Modest activities are displayed by compound 12 against A. niger at a MIC value of 12.5 μg/mL, whereas it exhibits strong activities against K. pneumonia and M. gypseum at a MIC value of 6.25 μg/mL. In vitro antitubercular activity screening was evaluated against M. tuberculosis H 37 Rv, INH-resistant M. tuberculosis by luciferase reporter phage assay method at two Scheme 2 Synthesis of 1,1'-(5,5'-(1,4-phenylene)bis(3-aryl-1H-pyrazole-5,1-(4H,5H)-diyl))diethanones under thermal and sonication methods using anhydrous sodium acetate/acetic anhydride.
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Conclusion
A clean, efficient, convenient, and economical synthesis of 1,1'-(5,5'-(1,4-phenylene)bis(3-aryl-1H-pyrazole-5,1-(4H,5H)-diyl))diethanones using ultrasound irradiation is described. The microbiological screening studies carried out to evaluate the antibacterial and antifungal potencies of the synthesized 1,1'-(5,5'-(1,4-phenylene)bis(3-aryl-1H-pyrazole-5,1-(4H,5H)-diyl))diethanones 7-12 were clearly known from Tables 2 and 3 . In vitro antibacterial and antifungal activities profile of substituted aromatics (X = F, Cl, Br) are more active than non-substituted aromatic ring system (X = H) of novel target compounds exerted strong antibacterial and antifungal activity against all the tested bacterial strains. Among all the tested compounds, electron withdrawing-substituted compounds 8, 9, and 
